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Introduction: To overcome the blood–brain barrier (BBB) which interferes with the effect
of chemotherapeutic agents, we performed multiple disruptions of BBB (BBBD) with
magnetic resonance-guided focused ultrasound on patients with glioblastoma (GBM)
during standard adjuvant temozolomide (TMZ) chemotherapy [clinical trial registration
no.NCT03712293 (clinicaltrials.gov)]. We report a 1-year follow-up result of BBBD with
TMZ for GBM.
Methods: From September 2018 to January 2019, six patients were enrolled (four men
and two women, median age: 53 years, range: 50–67 years). Of the six patients, five
underwent a total of six cycles of BBBD during standard TMZ adjuvant therapy. One
patient underwent three cycles of BBBD but continued with TMZ chemotherapy. The
1-year follow-up results of these six patients were reviewed.
Results: The mean follow-up duration was 15.17 ± 1.72 months. Two patients showed
a recurrence of tumor at 11 and 16 months, respectively. One underwent surgery, and
the other patient was restarted with TMZ chemotherapy due to the tumor location with a
highly possibility of surgical complications. The survival rate up to 1 year was 100%, and
the other four patients are on observation without recurrence. None of the six patients
had immediate or delayed BBBD-related complications.
Conclusion: Multiple BBBDs can be regarded as a safe procedure without long-term
complications, and it seems to have some survival benefits. However, since TMZ partially
crosses the BBB, a further extended study with large numbers would be needed to
evaluate the benefits of BBBD resulting in an increase of TMZ concentration. This
study opened a new therapeutic strategy for GBM by combining BBBD with a larger
molecular agent.
Keywords: glioblastoma multiforme, progression-free survival, blood–brain barrier, focused ultrasound, magnetic
resonance images
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INTRODUCTION
Glioblastoma (GBM) is one of the most common and malignant
primary brain tumors, making up 54% of all gliomas and 16%
of all primary brain tumors (1). Its survival rate is low due to its
aggressive nature in spite of the numerous efforts to overcome
GBM with chemotherapeutic agents. Despite the use of standard
treatment regimens since the 2000s, the median survival still
remains to be 14 to 15 months only (2, 3).
One of the main reasons for this ineffectiveness of the
chemotherapeutic agents is the presence of the blood–brain
barrier (BBB). The BBB mechanically and biochemically
restricts the passage of molecules. Furthermore, the
peritumoral area is commonly infiltrated with tumor
cells, but the BBB of this lesion is mostly intact. The
infiltrative nature of GBM makes additional difficulties for
the delivery of chemotherapeutic agents into the aimed
targets (4).
Tumor treating fields (TTF) lead to tumor cell death or arrest,
hypothetically by disrupting mitotic spindle formation and cell
division with alternating electric fields to the tumor. The TTF
was introduced in a pilot clinical trial for glial tumor in 2007
as a new treatment modality that is not affected by the presence
of the BBB (5). A clinical trial showed some survival benefits
of TTF on newly diagnosed GBM, whereas it did not show any
benefit on recurrent tumors. Thus, some neuro-oncologists and
neurosurgeons are still skeptical about TTF (6).
Recently, magnetic resonance-guided focused ultrasound
(MRgFUS) with low-intensity energy has been attracting
attention clinically as a non-invasive means of temporarily
disrupting the BBB. Since it has been found that the transcranial
delivery of ultrasound into the brain is feasible and low-intensity
ultrasound can temporarily open the BBB, many preclinical
studies have been conducted (7, 8). In the preclinical studies, the
survival rate of the animal model for glial tumor or metastatic
brain tumor increased when the drug was delivered with BBB
disruption (BBBD) (9, 10). Since then, many clinical studies have
been conducted withMRgFUS as a newmodality to overcome the
BBB (11–13). With its safety and feasibility confirmed, we tried to
disrupt the BBB to improve the therapeutic effect in GBM during
six cycles of standard temozolomide (TMZ) chemotherapy
period for the first time in the world (13). We hereby report the
1-year follow-up results of BBBD with MRgFUS on GBM.
MATERIALS AND METHODS
Six patients were enrolled from September 2018 to January
2019. The patients who underwent grossly total surgical resection
(GTR) of tumor confirmed as grade IV malignant glioma by
a neuropathologist were included. The patients received BBBD
during the six cycles of chemotherapy of the standard TMZ
treatment regimen. One cycle was defined as 28 days, and a total
of six cycles were applied in the TMZ regimen of this study. On
the first cycle, 150 mg/m2 of TMZ per day was taken for the first
5 days (days 1–5). On the following 2nd to 6th cycles, a dose of
200 mg/m2 was taken as maintenance dosage for the first 5 days
of each cycle. BBBD was performed on the first or the second day
of the 4-week chemotherapy cycle (Figure 1).
The BBBD target was selected within 2 cm of the tumor
margin, mainly on white matter with high signal intensity on the
fluid attenuated inversion recovery images. An average of 4.4 ±
0.9 BBBD targets was selected per patient without overlapping
margin by a neurosurgeon and a neuroradiologist with a pre-
sonication MRI. The BBBD was performed on 1 cm3 per target
and on the same targets for every cycle. BBBD was performed
using the ExAblate low-frequency MRgFUS system (ExAblate
Neuro Model 4000 Type 2.0 220 kHz system, InSightec, Haifa,
Israel). MRgFUS was performed with an intraoperative MRI
based on the stereotactic frame. Ultrasound was delivered with
an intravenous injection of microbubble. The bubble activity
was monitored in real-time during sonication. Sonication was
performed for about 210 s per target.
MRI was performed before and after each BBBD treatment
and at 6 months after the 6th cycle of chemotherapy.
The feasibility of BBB was determined by comparing T1-
enhanced or T2∗/GRE MRI before and immediately after the
procedure. All performed MRI were used to identify the
immediate or the delayed radiological adverse events and to
assess tumor status according to the Response Assessment
in Neuro-Oncology criteria. This study was approved by
our institutional review board (1-2018-0040), and patient’s
informed consent was obtained [clinical trial registration no.
NCT03712293 (clinicaltrials.gov)].
Five of the six patients underwent a total of six cycles of BBBD
during standard TMZ adjuvant therapy. One patient dropped out
after three sessions of BBBD, but the patient still continued with
the TMZ chemotherapy. The 1-year follow-up results focusing
on the outcome and the complications of these six patients
were reviewed.
RESULTS
Six patients (four men and two women, median age: 53
years, range: 50–67 years) were followed up for an average
of 12.17 ± 1.94 months from the beginning of their first
BBBD. It is on average 15.17 months from the initial diagnosis
of GBM (minimum 13 months, maximum 18 months). The
demographics of the patients who underwent BBBD are shown
in Table 1. BBBD was confirmed by post-sonication MRI in
the median of 94.3% of the target (minimum 70.8%, maximum
100%) during the six cycles of BBBD (13).
From the more than 1 year of follow-up period, two
patients showed recurrence at 11 and 16 months of follow-up,
respectively. The other four patients showed no recurrence for
an average of 15 months (Figure 2). The survival rate up to 13
months was 100%. None of the six patients had immediate or
delayed BBBD-related complications (Table 2).
CASE DESCRIPTION
Patient 1
Two months after the completion of all six cycles of BBBD,
patient 1 demonstrated a mild motor weakness of the right
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FIGURE 1 | Overview of the study. CCRT, concurrent chemoradiation therapy; BBBD, blood–brain barrier disruption; TMZ, temozolomide; MRI, magnetic resonance
imaging.
TABLE 1 | Patients demographics.






Patient 1 53 F Lt.F Wild + – – No deficit
Patient 2 62 M Rt.T Wild + – – No deficit
Patient 3 53 M Rt.P Wild – – – No deficit
Patient 4 67 M Lt.T Wild + – – No deficit
Patient 5 50 M Lt.P Wild + – – No deficit
Patient 6 50 F Rt.P Wild – – – No deficit
IDH, Isocitrate dehydrogenase; MGMT, Methylguanine–DNA methyltransferase promoter; EGFR, Epidermal growth factor receptor.
FIGURE 2 | Axial MRI images at pretreatment and at 1 year after the chemotherapy of patients 2, 3, 4, and 5. (A,B) Pre- and post-treatment MRI of patient 2,
respectively. (C,D) Pre- and post-treatment MRI of patient 3, respectively. (E,F) Pre- and post-treatment MRI of patient 4, respectively. (G,H) Pre- and post-treatment
MRI of patient 5, respectively.
leg. Pseudoprogression (PsP) of the tumor at the site of
the BBBD was observed on MRI. The neurological symptom
disappeared after steroid therapy. On the 3-month follow-
up MRI, the enhanced lesion showed a decrease in size
(Figure 3). The symptoms reappeared over time and a follow-
up MRI showed the recurrence of GBM at 16 months
from its first diagnosis, i.e., 8 months from the completion
of BBBD (Figure 3). The patient was restarted with TMZ
chemotherapy because the surgical resection had a high
possibility of complication due to the location of the tumor
mass. The patient is currently under observation, with right side
motor weakness.
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Survival Recurrence MRgFUS related
complications
Patient 1 18 + + –
Patient 2 15 + – –
Patient 3 16 + – –
Patient 4 15 + – –
Patient 5 14 + – –
Patient 6 13 + + –
BBBD, blood-brain barrier disruption; MRgFUS, Magnetic resonance guided
focused ultrasound.
Patients 2, 3, and 5
The patients completed six cycles of chemotherapy and BBBD
without any adverse events or recurrence of the tumor and
have been observed as in a clinically and radiologically stable
disease state.
Patient 4
The patient had a GBM on the left temporal area and
demonstrated a minor personality issue before enrollment. After
three cycles of BBBD, the patient dropped out from the study.
However, he still continued on the TMZ chemotherapy for the
remaining three cycles. He has been observed as in a stable
disease state without any findings of recurrence on the MRI
performed at 6months after the completion of chemotherapy and
clinical evaluation.
Patient 6
After completion of the chemotherapy, the patient had no
neurological deficit and showed a stable disease state without
evidence of recurrence on MRI. However, at 2 months later,
i.e., 11 months from the initial diagnosis of GBM, the
patient complained of left motor weakness and a recurrence
at the right temporal lobe was observed on follow-up MRI
(Figure 4). Surgical resection was done and chemotherapy is
in progress.
DISCUSSION
GBM is one of the most common but also one of the most lethal
malignant brain tumors. It occurs in the cortex, grows invasively
and aggressively, invades the lobes, and affects the deep structures
of the brain (14). Due to these characteristics, patients with
GBMhave short recurrence-free interval, short survival time, and
poor prognosis. Prior to the release of the currently used drug,
TMZ, its treatment consisted of surgical resection followed by
radiation therapy, yielding a median survival between 9 to 12
months (15–17).
Brain tumors are not well-controlled with therapeutic agents
because of the BBB. The BBB, a barrier formed by tight junctions
of endothelial cells, imposes size, and biochemical restrictions
on molecule passage. Therefore, large and hydrophilic molecules
cannot pass through the BBB, whereas small lipid-soluble
drugs below 400 Da can (18). The TMZ molecule is 194
Da in size and lipophilic, available for better central nervous
system penetration compared to other alkylating agents (19).
Due to these characteristics, the present standard treatment
regimen for GBM is surgery, radiotherapy, and chemotherapy
of concomitant and six cycles of adjuvant TMZ (20). After
the introduction of TMZ and the currently used regimen,
the median survival has increased up to 14.6 months, the 2-
year survival rate up to 27.2%, and the 5-year survival up to
10% (20, 21).
Many efforts have been made to increase the survival
rates, but they have been unsuccessful. Changing the
dose frequency or delivery method, such as intra-arterial
delivery with chemotherapeutic agents, resulted in higher
toxicity rates without improving patient outcome (22, 23). In
addition, spatially non-specific methods, such as convection-
enhanced delivery or wafer, had adverse effects on normal
brain tissue (4). Recently, several studies have shown that
a very low intensity of ultrasound can disrupt the BBB
without damaging the surrounding brain tissues (8, 11).
Since then, many studies have been conducted using
MRgFUS as a non-invasive means of temporarily disrupting
the BBB.
Although TMZ can pass through the BBB, the concentration
of TMZ in brain tumor tissue is about 20% of the plasma
level (19). Even with the concurrent radiation therapy which
is performed to improve the BBB penetration of TMZ, the
concentration may rise only up to 35% of the plasma level
(24). A previous study demonstrated that BBBD has made a
7.7-fold difference of TMZ concentration between the sonicated
and the unsonicated areas of a patient (12). Therefore, we
tried to increase the effect of tumor control by BBBD
using MRgFUS.
Previous studies postulate that GBM generally recurs at a
median of 7–7.5 months after a primary treatment and has
an average survival of 12.8–14.6 months (25, 26). A recent
meta-analysis showed that the progression-free survival (PFS) is
66.5% at 6 months and 46.8% at 1 year, with 55.9% of 1-year
overall survival rate when total gross removal is performed for
GBM (27). When GBM is subtotally removed, this is lowered
to 51.3, 23.3, and 39.8%, respectively. All six patients in this
study underwent GTR of tumor. Although two of the six
patients had a recurrence, they showed 100% of 6-month PFS
and 83.3% of 1-year PFS, which is better than the previously
reported meta-analysis. The average PFS of the patients who
had a recurrence was 13.5 months, whereas the others showed a
median PFS of at least 15 months. This is twice the previously
reported PFS and is likely to increase. In addition, the 1-year
overall survival was 100%. Regarding these results, the survival
benefit of additional BBBD to increase TMZ concentration may
be considered.
One of the factors affecting the effect of TMZ is the presence
of O6-methylguanine-DNA methyltransferase (MGMT) gene
methylation. The MGMT is a DNA repair protein. The
methylation of MGMT promoter is associated with the loss of
MGMT expression, diminished DNA repairing activity induced
by alkylating agents, and longer survival (28, 29). Of the four
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FIGURE 3 | Pseudoprogression and recurrence of glioblastoma (GBM) in patient 1 after six cycles of adjuvant temozolomide (TMZ) chemotherapy and blood–brain
barrier disruption. After the six cycles of adjuvant TMZ chemotherapy, a newly developed enhanced lesion at the left cingulate gyrus was observed on
contrast-enhanced T1-weighted MRI (A). However, relative cerebral blood volume (B) and volume transfer coefficient (Ktrans) (C) maps showed no increase of
metrics, suggesting pseudoprogression. At 4 months later, MRI was performed due to the reappearance of symptoms. On contrast-enhanced T1-weighted MRI (D), a
larger enhanced mass with elevated Ktrans (E) and increased cerebral blood volume (F) are shown.
patients without progression during the follow-up period, three
patients had MGMT methylated status. In addition, of the
patients with recurrent GBM, one patient with methylated
MGMT promoter had a recurrence at 16 months and the other
patient with unmethylated MGMT promoter had a recurrence
at 11 months after the initial diagnosis. Thus, even with BBBD,
patients with methylatedMGMT promoter seem to show a better
clinical course and treatment results despite the fact that it is
difficult to identify the significant correlation between MGMT
promoter methylation and recurrence or survival due to the
small size of the study. However, our study results show that
75% of patients (3/4) with methylated MGMT promoter had no
evidence of recurrence for an average of 14.7 months, whereas
50% of patients (1/2) with unmethylated MGMT promoter had
no recurrence for an average of 16 months. Therefore, the
increased survival benefits of elevated TMZ concentration due to
BBBD in patients with unmethylated MGMT promoter should
be emphasized.
Despite that the results of multiple BBBDs in addition to TMZ
have been positive to date with survival benefit, a more careful
approach is needed to evaluate the benefits of BBBD, resulting in
an increase of TMZ concentration. A long-term follow-up study
beyond the commonly reported median survival period and a
further extended study with a larger number would be needed
to determine how positively BBBD affects the survival period
of GBM.
There were no short-term or long-term complications
associated with BBBD during the 15 months of median follow-
up period in this study. Many studies have reported that
BBBD with MRgFUS is safe without complications (11, 12).
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FIGURE 4 | Axial MRI images of patient 6 at 3 months (before chemotherapy), 9 months (after the completion of chemotherapy), and 11 months after the initial
diagnosis of glioblastoma, respectively.
It has also been reported that multiple BBBDs have been
performed without short-term complications (13). This study
confirmed that the long-term follow-up result of multiple
BBBDs is safe and without complications such as radiological
adverse events or TMZ-related neurotoxicity or clinically
adverse events.
In one patient, PsP was observed at the site of the BBBD
after six cycles of adjuvant TMZ chemotherapy. The PsP is a
subacute treatment-related effect, which usually occurs within
3 months of completion of chemoradiation in 15 to 30%
of patients (30, 31). It likely reflects an inflammatory post-
procedure tissue reaction after a successful local treatment,
followed by long-lasting tumor control. The presence of MGMT
promoter methylation is associated with PsP (30). A patient with
PsP in this study had MGMT methylated status. However, it
took 8 months before PsP was observed after the completion
of chemoradiation, whereas it usually occurs within 3 months
after chemoradiation. Recurrence was noted afterwards. There
are several possibilities on whether PsP occurs as a local
inflammation related to tumor control of BBBD or is caused
by BBBD regardless of the underlying disease and whether
BBBD affects the timing of PsP or recurrence. Therefore,
additional follow-up will be needed and further research on the
relationship and the mechanism between BBBD and PsP would
be required.
In conclusion, multiple BBBDs can be regarded as a
safe procedure without long-term complication, and it
seems to have some survival benefits. This study opened
a new therapeutic strategy for GBM by combining BBBD
with a therapeutic agent which could not be used due
to BBB.
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